Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
37 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
AiCuris GmbH & Co. KG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AiCuris GmbH & Co. KG - Product Pipeline Review - 2014', provides an overview of the AiCuris GmbH & Co. KG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of AiCuris GmbH & Co. KG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of AiCuris GmbH & Co. KG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of AiCuris GmbH & Co. KG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the AiCuris GmbH & Co. KG's pipeline products Reasons to buy - Evaluate AiCuris GmbH & Co. KG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of AiCuris GmbH & Co. KG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the AiCuris GmbH & Co. KG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of AiCuris GmbH & Co. KG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of AiCuris GmbH & Co. KG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of AiCuris GmbH & Co. KG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 AiCuris GmbH & Co. KG Snapshot 5 AiCuris GmbH & Co. KG Overview 5 Key Information 5 Key Facts 5 AiCuris GmbH & Co. KG - Research and Development Overview 6 Key Therapeutic Areas 6 AiCuris GmbH & Co. KG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 AiCuris GmbH & Co. KG - Pipeline Products Glance 13 AiCuris GmbH & Co. KG - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 AiCuris GmbH & Co. KG - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 AiCuris GmbH & Co. KG - Drug Profiles 17 pritelivir 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 AIC-292 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Drug for Autoimmune Disorders 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 AIC-649 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Small Molecule 1 for Gram-Negative Bacterial Infections 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Small Molecule to Inhibit Reverse Transcriptase for HIV 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecule 2 for Gram-Negative Bacterial Infections 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecule 3 for Gram-Negative Bacterial Infections 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecule for Bacteral Infections 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecule for Gram-Positive Bacterial Infections 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecule for Infectious Disease 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecule for Viral Infections 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 AiCuris GmbH & Co. KG - Pipeline Analysis 29 AiCuris GmbH & Co. KG - Pipeline Products by Target 29 AiCuris GmbH & Co. KG - Pipeline Products by Route of Administration 30 AiCuris GmbH & Co. KG - Pipeline Products by Molecule Type 31 AiCuris GmbH & Co. KG - Pipeline Products by Mechanism of Action 32 AiCuris GmbH & Co. KG - Recent Pipeline Updates 33 AiCuris GmbH & Co. KG - Dormant Projects 34 AiCuris GmbH & Co. KG - Locations And Subsidiaries 35 Head Office 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 37 Disclaimer 37
List of Tables AiCuris GmbH & Co. KG, Key Information 5 AiCuris GmbH & Co. KG, Key Facts 5 AiCuris GmbH & Co. KG - Pipeline by Indication, 2014 8 AiCuris GmbH & Co. KG - Pipeline by Stage of Development, 2014 9 AiCuris GmbH & Co. KG - Monotherapy Products in Pipeline, 2014 10 AiCuris GmbH & Co. KG - Out-Licensed Products in Pipeline, 2014 11 AiCuris GmbH & Co. KG - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 AiCuris GmbH & Co. KG - Phase II, 2014 13 AiCuris GmbH & Co. KG - Phase I, 2014 14 AiCuris GmbH & Co. KG - Preclinical, 2014 15 AiCuris GmbH & Co. KG - Discovery, 2014 16 AiCuris GmbH & Co. KG - Pipeline by Target, 2014 29 AiCuris GmbH & Co. KG - Pipeline by Route of Administration, 2014 30 AiCuris GmbH & Co. KG - Pipeline by Molecule Type, 2014 31 AiCuris GmbH & Co. KG - Pipeline Products by Mechanism of Action, 2014 32 AiCuris GmbH & Co. KG - Recent Pipeline Updates, 2014 33 AiCuris GmbH & Co. KG - Dormant Developmental Projects,2014 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.